The unique molecular targets associated antioxidant and antifibrotic activity of curcumin in in vitro model of acute lung injury: A proteomic approach

Biofactors. 2021 Jul;47(4):627-644. doi: 10.1002/biof.1732. Epub 2021 Apr 17.

Abstract

Bleomycin (BLM) injury is associated with the severity of acute lung injury (ALI) leading to fibrosis, a high-morbidity, and high-mortality respiratory disease of unknown etiology. BLM-induced ALI is marked by the activation of a potent fibrogenic cytokine transcription growth factor beta-1 (TGFβ-1), which is considered a critical cytokine in the progression of alveolar injury. Previously, our work demonstrated that a diet-derived compound curcumin (diferuloylmethane), represents its antioxidative and antifibrotic application in TGF-β1-mediated BLM-induced alveolar basal epithelial cells. However, curcumin-specific protein targets, as well as its mechanism using mass spectrometry-based proteomic approach, remain elusive. To elucidate the underlying mechanism, a quantitative proteomics approach and bioinformatics analysis were employed to identify the protein targets of curcumin in BLM or TGF-β1-treated cells. With subsequent in vitro experiments, curcumin-related pathways and cellular processes were predicted and validated. The current study discusses two separate proteomics experiments using BLM and TGF-β1-treated cells with the proteomics approach, various unique target proteins were identified, and proteomic analysis revealed that curcumin reversed the expressions of unique proteins like DNA topoisomerase 2-alpha (TOP2A), kinesin-like protein (KIF11), centromere protein F (CENPF), and so on BLM or TGF-β1 injury. For the first time, the current study reveals that curcumin restores TGF-β1 induced peroxisomes like PEX-13, PEX-14, PEX-19, and ACOX1. This was verified by subsequent in vitro assays. This study generated molecular evidence to deepen our understanding of the therapeutic role of curcumin at the proteomic level and may be useful to identify molecular targets for future drug discovery.

Keywords: acute lung injury; bleomycin; curcumin; proteomics; transforming growth factor-beta 1.

MeSH terms

  • A549 Cells
  • Acetyl-CoA C-Acetyltransferase / genetics
  • Acetyl-CoA C-Acetyltransferase / metabolism
  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / genetics
  • Acute Lung Injury / pathology
  • Acute Lung Injury / prevention & control
  • Acyl-CoA Oxidase / genetics
  • Acyl-CoA Oxidase / metabolism
  • Antibiotics, Antineoplastic / pharmacology
  • Antioxidants / chemistry
  • Antioxidants / metabolism
  • Antioxidants / pharmacology*
  • Autoantigens / genetics
  • Autoantigens / metabolism
  • Binding Sites
  • Bleomycin / antagonists & inhibitors*
  • Bleomycin / pharmacology
  • Calreticulin / genetics
  • Calreticulin / metabolism
  • Collagen Type XVII
  • Curcumin / chemistry
  • Curcumin / metabolism
  • Curcumin / pharmacology*
  • Gene Expression Regulation
  • Gene Regulatory Networks
  • Humans
  • Kinesins / genetics
  • Kinesins / metabolism
  • Models, Biological
  • Molecular Docking Simulation
  • Non-Fibrillar Collagens / genetics
  • Non-Fibrillar Collagens / metabolism
  • Protein Binding
  • Protein Conformation, alpha-Helical
  • Protein Conformation, beta-Strand
  • Proteomics / methods*
  • Receptor, IGF Type 1 / genetics
  • Receptor, IGF Type 1 / metabolism
  • Receptor, IGF Type 2 / genetics
  • Receptor, IGF Type 2 / metabolism
  • Signal Transduction
  • Transforming Growth Factor beta1 / antagonists & inhibitors*
  • Transforming Growth Factor beta1 / pharmacology

Substances

  • Antibiotics, Antineoplastic
  • Antioxidants
  • Autoantigens
  • CALR protein, human
  • Calreticulin
  • IGF1R protein, human
  • IGF2R protein, human
  • KIF11 protein, human
  • Non-Fibrillar Collagens
  • Receptor, IGF Type 2
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Bleomycin
  • Acyl-CoA Oxidase
  • ACAT1 protein, human
  • Acetyl-CoA C-Acetyltransferase
  • Receptor, IGF Type 1
  • Kinesins
  • Curcumin